Pontocerebellar hypoplasia (PCH) represents a group (PCH1-6) of neurodegenerative autosomal recessive disorders characterized by hypoplasia and/or atrophy of the cerebellum, hypoplasia of the ventral pons, progressive microcephaly and variable neocortical atrophy. The majority of PCH2 and PCH4 cases are caused by mutations in the TSEN54 gene; one of the four subunits comprising the tRNA-splicing endonuclease (TSEN) complex. We hypothesized that TSEN54 mutations act through a loss of function mechanism. At 8 weeks of gestation, human TSEN54 is expressed ubiquitously in the brain, yet strong expression is seen within the telencephalon and metencephalon. Comparable expression patterns for tsen54 are observed in zebrafish embryos. Morpholino (MO) knockdown of tsen54 in zebrafish embryos results in loss of structural definition in the brain. This phenotype was partially rescued by co-injecting the MO with human TSEN54 mRNA. A developmental patterning defect was not associated with tsen54 knockdown; however, an increase in cell death within the brain was observed, thus bearing resemblance to PCH pathophysiology. Additionally, N-methyl-N-nitrosourea mutant zebrafish homozygous for a tsen54 premature stop-codon mutation die within 9 days post-fertilization. To determine whether a common disease pathway exists between TSEN54 and other PCH-related genes, we also monitored the effects of mitochondrial arginyl-tRNA synthetase (rars2; PCH1 and PCH6) knockdown in zebrafish. Comparable brain phenotypes were observed following the inhibition of both genes. These data strongly support the hypothesis that TSEN54 mutations cause PCH through a loss of function mechanism. Also we suggest that a common disease pathway may exist between TSEN54-and RARS2-related PCH, which may involve a tRNA processing-related mechanism.
INTRODUCTION
Pontocerebellar hypoplasia (PCH) represents a group of neurodegenerative autosomal recessive disorders characterized by severe mental and motor impairments. The disease is associated with prenatal onset, hypoplasia/atrophy of the cerebellum, hypoplasia of the ventral pons, progressive microcephaly and variable neocortical atrophy. The median life expectancy is * To whom correspondence should be addressed at: Department of Genome Analysis, Academic Medical Center, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands. Tel: +31 205663846; Fax: +31 205669312; Email: f.baas@amc.uva.nl 50 months (1); however, in rare cases, the most severe forms can lead to fatality during early post-natal periods. To date, six subtypes of PCH (PCH1 -6) have been distinguished based on varying clinical and pathological features (1 -6) .
Mutations in three of the four subunit genes comprising the tRNA-splicing endonuclease (TSEN) complex are responsible for PCH2 and PCH4 (1, 2) . The TSEN complex is a heterotetramic enzyme comprised of two structural subunits, TSEN54 and TSEN15, and two catalytic subunits, TSEN2 and TSEN34 (7, 8) . Mutations in the TSEN54 subunit gene are the most frequent cause of PCH2 and PCH4, and a common mutation (p.A307S) has been identified in the majority of patients. A homozygous p.A307S mutation is strongly associated with a PCH2 phenotype. The p.A307S mutation occurring compound heterozygous with a TSEN54 null allele is associated with a severe PCH4 phenotype (1) . Other less common TSEN54 mutations, as well as rare mutations occurring in the TSEN2 and TSEN34 subunit genes have also been identified in PCH2 and PCH4 cases (1, 2) .
tRNAs play an essential role in protein synthesis where the anticodon of a mature tRNA molecule recognizes and interacts with the codon displayed by the mRNA. Through the activity of the ribosome, this process allows condensation of the tRNA-specific amino acid with the peptide chain on the adjacent tRNA (9) . Part of the maturation process is the removal of an intronic sequence that exists within the anticodon loop of some tRNA genes. Splicing of the intron is performed through a composite active site of the TSEN complex (8) . In humans, only 6.2% of tRNA genes contain an intron and therefore require TSEN function for maturation and exposure of the anticodon, necessary for downstream translation. Multiple genes exist for each tRNA and in some circumstances the vast majority or all tRNA genes for a particular codon are intron-containing. For example, in humans, 13 of the 14 genes encoding tRNA Tyr -(GTA) contain an intron. Therefore, a defective TSEN complex is likely to lead to a shortage of tRNA tyrosine. Other examples exist including tRNA Ile -(TAT), tRNA Leu -(CAA) and tRNA Arg -(TCT). More details can be viewed at http://lowelab.ucsc.edu/GtRNAdb/.
In most cases, PCH4 patients, who are more severely affected than PCH2 patients, have a null allele and a missense mutation in the TSEN54 subunit gene (1) . This genotypephenotype observation supports a hypothesis for a loss of TSEN function in PCH2 and PCH4 pathophysiology. The TSEN complex is not only involved in tRNA splicing. It also plays a role in mRNA 3 ′ end formation (7) . Therefore, it is possible that other functions of the TSEN complex may play a role in the disease pathogenesis of PCH2 and PCH4 cases.
How mutations in a gene involved with tRNA splicing and protein synthesis can lead to a brain-specific defect is unclear. TSEN54 is expressed throughout the body; however, there are differences in expression levels between various tissues (http://www.genecards.org/cgi-bin/carddisp.pl?gene=TSEN54& search=tsen54). Strong TSEN54 mRNA expression has been observed in neuronal populations in the developing cerebellum, pons and olivary nuclei at 23 weeks of gestation (2) . This and the selective degeneration in PCH could suggest that TSEN activity is required at high levels in the brain structures affected in the disease. At 23 weeks of gestation, the brain has already significantly increased in volume and is well established neuroanatomically (10) . Neonatal ultrasound analysis in PCH2 patients reveals that the cerebellum develops as normal to gestation week 29; however, from gestation week 31, cerebellar hypoplasia can be observed (11) . In addition, cell death in the pons has been reported in PCH patients at low levels following pathological examination (5) . It is likely that high levels of degeneration are present during the time course of disease; however, most cells will have degenerated at the time of death and are thus unavailable for post-mortem analysis.
As PCH is a rare and lethal neurodegenerative disorder, patient material is scarce. To further understand the role of TSEN in the pathophysiology of PCH, a disease model is required. Zebrafish are now a well-established tool used to model various neurodegenerative disorders (12) . In this current study, we have utilized two separate genetic approaches to produce zebrafish models of TSEN54-related PCH. These include an antisense morpholino (MO) oligonucleotide-induced knockdown of tsen54 and also an N-methyl-N-nitrosourea (ENU) mutagenesis strategy to produce a zebrafish strain harbouring a tsen54 premature stopcodon mutation. Here, we show that the knockdown of tsen54 results in brain hypoplasia and loss of structural definition in the brain, which is associated with increased cell death but not a developmental patterning defect, whereas genetic knockout of tsen54 is lethal. Additionally, the knockdown of the mitochondrial arginyl-tRNA synthetase (rars2) gene, (RARS2 mutations cause PCH1 and PCH6) (1,4,13) results in a phenotype that is comparable with tsen54 depletion. Using these novel disease models of PCH, we provide the first evidence in an experimental model that TSEN54 mutations act through a loss of function mechanism and that a common disease pathway may exist between PCH subtypes due to either TSEN54 or RARS2 mutations.
RESULTS

TSEN54 expression during early development in human and zebrafish
To examine TSEN54 expression during early brain development, we performed in situ hybridization on 8-week-old human fetal brain sections using TSEN54-specific locked nucleic acid/2 ′ -O-methyl RNA (LNA/2OME) probes. TSEN54 mRNA is expressed throughout the brain at this early stage, with high levels of expression observed within the developing telencephalon and metencephalon (Fig. 1A) . During normal development, the metencephalon later forms the pons and cerebellum (14) . Analysis of other tissues shows relatively high TSEN54 expression in spinal cord and liver, whereas expression in other tissues was low (Supplementary Material, Fig. S1 ). We next examined the expression pattern of zebrafish tsen54 in embryos at 24 h post-fertilization (hpf). The zebrafish TSEN54 orthologue (also known as zgc: 109927; accession number: NM_001020529) shares 46% identity to the human gene. As shown in Figure 1B , tsen54 expression is ubiquitous, with strong expression in the brain within the telencephalon and midhindbrain boundary (MHB). tsen54 is also expressed ubiquitously during early embryogenesis in zebrafish as observed from the 8-cell stage to the somite stages (Supplementary Material, Fig. S2 ).
MO knockdown of tsen54 causes loss of structural integrity in the zebrafish brain As TSEN54-related PCH is inherited in an autosomal recessive manner, the biological mechanism underlying the disease is likely to be associated with a loss of TSEN54 function. To test this hypothesis in a model system, we were interested in monitoring the effects of knocking down the zebrafish tsen54 gene using an antisense MO oligonucleotide approach. In comparison to wild-type (WT) un-injected ( Fig. 2A ) and control MO (CoMO)-injected embryos (Fig. 2B ) at 24 hpf, injection of 2.5 ng tsen54 translation blocking (ATG) MO (Fig. 2C ) resulted in abnormalities within the head including brain hypoplasia and loss of structural integrity inside the brain. Clear structural definition of the MHB (denoted by an asterisk) was apparent in the control embryos ( Fig. 2A and B) ; however, this structure appeared aberrant in tsen54 morphants ( Fig. 2C and D) . In zebrafish embryos, the MHB is a key structure involved with the neuronal migration and the development of the cerebellum (15) . To exclude the possibility that the effect was due to a nonspecific effect and to confirm specific targeting of the MO (16), we designed a second tsen54 MO that targeted the exon 8 splice donor site of the tsen54 gene. As shown in Figure 2D , we observe comparable brain hypoplasia and reduced structural definition in splice-site morphants. Reverse transcriptase -polymerase chain reaction (RT -PCR) of cDNA synthesized from WT, CoMO and splice-site morphant embryos confirmed abnormal splicing of the tsen54 gene in the morphants (Fig. 2G) . To further confirm that the phenotype was directly attributable to the knockdown of tsen54, we attempted to rescue the brain phenotype associated with tsen54 depletion by co-injecting the ATG MO with human TSEN54 mRNA. As shown in Figure 2E , injection of 233 pg human TSEN54 mRNA alone produced no effects upon brain structure. Co-injection of tsen54 ATG MO and human TSEN54 mRNA resulted in a partial rescue of the brain phenotype observed with MO only (Fig. 2F ). Co-injected embryos display generally milder brain hypoplasia and more clearly defined brain structure when compared with ATG alone (Fig. 2C) . We next quantified the proportion of brain phenotypes associated with each treatment at 24 hpf (Fig. 2H ). Brain phenotypes were classified as either normal (appeared as WT), mild (slight brain hypoplasia, slight reduction in structural definition in the brain) or severe (severe brain hypoplasia, complete loss of brain structural definition). As expected, predominantly normal brain phenotypes were associated with both control groups (WT un-injected, human TSEN54 mRNA only). Knockdown of tsen54 with the ATG MO was associated with a mostly severe brain phenotype (76%), although mild (13%) and normal (11%) brain phenotypes were also observed to a lesser extent. Co-injection of the ATG MO with human TSEN54 mRNA resulted in a striking reduction in the proportion of embryos displaying a severe brain phenotype (8%) and a shift to a predominantly mild (67%) brain phenotype. Indeed, the percentage of normal brain phenotypes also increased (25%) within the rescue group. Therefore, human TSEN54 is capable of partially rescuing the brain phenotype associated with the loss of tsen54 translation, thus confirming specific targeting of the MO.
Inhibition of tsen54 translation produces a brain defect which is not associated with a developmental patterning deficiency PCH is characterized by hypoplasia and atrophy of the cerebellar hemispheres, hypoplasia of the pons and a general delay of neurodevelopment (17) . To determine whether the brain phenotype caused by tsen54 knockdown in zebrafish embryos was associated with a developmental brain patterning defect, we performed in situ hybridization on whole-mount embryos at 24 hpf using fgf8 (fibroblast growth factor 8) and otx2 (orthodenticle homeobox 2) RNA probes as markers of brain development. In zebrafish brain, Fgf8 is expressed in the MHB and plays a role in the maintenance and development of this region, which includes the cerebellum (18) . In addition, Fgf8 is also expressed within the telencephalon and optic vesicles (19) . Otx2 plays a role in early regionalization of the mesencephalon and indeed is expressed within fore-midbrain regions during early development in zebrafish (20) . Abnormal localization of the expression of these genes within morphants would suggest a defect in the developmental patterning of these brain regions. As shown in Figure 3A , embryos injected with human TSEN54 mRNA alone show normal expression patterning of Fgf8. When the brain was observed from a dorsal perspective (Fig. 3D ), the expression of Fgf8 appeared as a 'horseshoe with a peak' pattern in control embryos. MO knockdown of tsen54 was not associated with abnormal patterning ( Fig. 3B ), as Fgf8 expression was correctly observed within the MHB and telencephalon. However, compared with controls, the MHB appeared compressed, thus reflecting the brain hypoplasia associated with tsen54 knockdown. This result is further supported when observing the dorsal view of the morphant brain where the 'peak' of the 'horseshoe' was absent from the MHB (Fig. 3E, arrow) . Loss of this horseshoe peak was reversed, to a certain extent, by co-injecting the tsen54 ATG MO with human TSEN54 Figure 1 . TSEN54 expression is ubiquitous but strong in the brain in human and zebrafish during early stages of neurodevelopment. (A) TSEN54 in situ hybridization within transverse section of a human foetal brain at 8 weeks prenatal age. TSEN54 mRNA is widely expressed throughout brain and head tissue, but strongly expressed in the developing metencephalon (m) and telencephalon (t). Scale bar ¼ 1 mm. (B) Lateral view of tsen54 whole-mount in situ hybridization in zebrafish embryo. Ubiquitous tsen54 mRNA expression pattern is observed at 24 hpf in zebrafish embryos, with strongest expression observed within the brain, especially the telencephalon (t) and mid-hindbrain boundary (mhb). Scale bar ¼ 200 mm.
mRNA, further confirming specific gene targeting ( Fig. 3C and F). Similarly, tsen54 knockdown did not result in abnormal patterning of the fore-midbrain as localization of Otx2 expression was comparable between morphants ( Fig. 3H ) and controls (Fig. 3G) . However, the brain hypoplasia phenotype was further illustrated by the reduction in intensity and extent of the Otx2 expression pattern in morphants compared with controls ( Fig. 3J and K), which could be partially rescued by the introduction of human TSEN54 mRNA ( Fig. 3I and L).
Brain phenotype caused by tsen54 knockdown is associated with increased cell death
As the brain phenotype caused by tsen54 knockdown was not associated with a neurodevelopmental patterning defect, we next monitored the levels of neurodegeneration in the brains of morphant embryos. Embryos were incubated with acridine orange, a vital dye that binds to nucleic acids in damaged cells (21) . The numbers of fluorescing cells within the brain were counted from 10 to 20 embryos per group (at 24 hpf). Low numbers of fluorescing cells were counted in the brains of WT embryos ( Fig. 4A and E; 55.5 + 4; mean + SEM) and TSEN54 mRNA-injected embryos ( Fig. 4B and E; 80.7 + 7). In comparison to both of the control groups, injection of the tsen54 ATG MO resulted in a significant increase in the number of fluorescing cells within the brain ( Fig. 4C and E; 242.9 + 16; P , 0.0001). Co-injection of tsen54 ATG MO with human TSEN54 mRNA resulted in a significant reduction in the numbers of fluorescing cells in comparison to the tsen54 ATG injection only group ( Fig. 4D and E; 173.9 + 7.8; P ¼ 0.0005); however, the number of fluorescing cells in this group was still significantly greater than that of both control groups (P , 0.0001). Therefore, this result further confirms that human TSEN54 is capable of partially rescuing the brain phenotype associated with tsen54 knockdown.
A homozygous premature stop-codon mutation within tsen54 causes early lethality in zebrafish Antisense MO oligonucleotides allow a highly efficient means of knocking down gene function during early embryonic development; however, the effects diminish after a few days post-fertilization (dpf) (12) . Therefore, we generated a stable zebrafish model that harboured a mutation within the tsen54 gene in order to study the survival rates. We screened the RT-PCR using primers located in exons 7 and 10 in tsen54 cDNA synthesized from RNA extractions from WT un-injected embryos, CoMO-injected embryos and tsen54 exon 8 splice donor site MO-injected embryos. RT-PCR using samples from control embryos produced a band of 696 bp in length. Shorter products observed in splice MO-injected embryos indicate abnormal splicing of the tsen54 gene. (H) Quantification of phenotypes observed in WT un-injected embryos, human TSEN54 mRNA-injected embryos, tsen54 ATG MO-injected embryos and rescued embryos co-injected with ATG MO and human mRNA. For each group, 50-100 embryos were analysed. Embryos were classified as displaying normal (white), mild (grey) or severe (black) phenotypes. There is a shift from a predominantly severe phenotype in the tsen54 ATG MO group to a predominantly mild phenotype in ATG MO and human TSEN54 mRNA co-injection group, thus illustrating the partial rescue of the brain phenotype associated with the loss of tsen54.
zebrafish ENU mutagenesis DNA archive at the Hubrecht Laboratories, Utrecht (22) , and identified a heterozygous C . T substitution in exon 8 of the tsen54 gene (c.682C . T; Fig. 5A ). The position of this mutation translates as the conversion of an arginine to a premature stop codon at amino acid position 228 (p.R228X). Heterozygotes from the F2 progeny were identified by genotyping and the mutation was backcrossed onto a WT AB background for five generations to reduce the number of potentially confounding ENU mutations (23) . All mutants from this breeding programme were subsequently referred to as tsen54 R228X . As PCH is an autosomal recessive disease, we next performed an in-cross between heterozygous mutants to test for homozygosity. Embryos resulting from the in-cross were genotyped at 1, 2 and 3 weeks post-fertilization. All three genotypes were present after 1 week; however, at 2 weeks post-fertilization, tsen54 R228X2/2 animals were absent, suggesting that homozygosity was lethal during the larval stages (data not shown). To determine the precise time point at which the lethality of tsen54 R228X2/2 larvae occurred, we performed a survival analysis. As shown in Fig. 5B , larvae obtained from a control WT TL in-cross showed 72% survival after 3 weeks, whereas only 45% of the tsen54 R228X+/+ embryos survived to 21 dpf, probably due to the retention of an ENU mutation on the tsen54 R228X+/+ background. Of the tsen54
heterozygous embryos, 62% survived to 21 dpf. Confirming our observations on the lethality of homozygosity for the mutation, all tsen54 R228X2/2 larvae had died by 9 dpf (Fig. 5B) .
Disruption of the rars2 gene results in a brain phenotype comparable with tsen54 morphants
Mutations in the nuclear-encoded RARS2 gene are found in PCH1 and PCH6 (1, 4, 13) . RARS2 plays a role in the aminoacylation of mitochondrial tRNA Arg (4). Thus, a common disease mechanism related to tRNA processing may account for different PCH subtypes caused by mutations in TSEN54 or RARS2. Similar to tsen54, rars2 is expressed ubiquitously at 24 hpf but strong within the head and brain (24) . To test the effects of rars2 inhibition, we injected zebrafish embryos with MOs designed to target the rars2 ATG start site and the exon 6 splice donor site. As shown in Figure 6C and D, knockdown of rars2 with both MOs results in brain hypoplasia and loss of structural definition within the brain in comparison to control embryos ( Fig. 6A and B) . RT -PCR reveals that abnormal splicing of rars2 occurred in the splice-site morphants (Fig. 6G) . Co-injection of human RARS2 mRNA with the rars2 ATG MO resulted in partial recovery of the brain phenotype, thus confirming specific targeting of gene knockdown (Fig. 6E, F and H) . Whole-mount in situ hybridization using fgf8 (Supplementary Material, Fig. S3A -F) and otx2 (Supplementary Material, Fig. S3G -L) RNA probes further illustrates the brain hypoplasia phenotype observed in rars2 morphants. Similar to tsen54 knockdown, developmental patterning of the MHB and the fore-midbrain regions was not affected. Furthermore, rars2 knockdown was associated with a significant increase in cell death within the brains of morphant embryos (Supplementary Material, Fig. S4C and E) when compared with both control groups (P , 0.0001; Supplementary Material, Fig. S4A, B and E). The number of dead cells was significantly reduced when human RARS2 mRNA was co-injected with the rars2 ATG MO (P ¼ 0.0005; Supplementary Material, Fig. S4D and E). Taken together, these observations reveal phenotypic comparisons between rars2 and tsen54 morphants, suggesting a common disease pathway may exist between two separate genes in the pathogenesis of distinct subtypes of PCH.
DISCUSSION
In this study, we show that the inhibition of tsen54 in zebrafish leads to neurological abnormalities and is lethal, thus bearing similarities to the disease characteristics associated with PCH. In addition, these data strongly support the hypothesis that TSEN54 mutations cause the disease through a loss of function mechanism. A strong and specific expression pattern for TSEN54 in developing human cerebellar neurons at gestation week 23 has been reported previously (2) . Here, we show that TSEN54 mRNA is ubiquitously expressed in the brain at 8 weeks of development with strong expression observed within the developing metencephalon and telencephalon. The metencephalonic region of the developing brain eventually forms the pons and cerebellum (25) . Abnormalities in both of these regions are the hallmark features of PCH pathology as all six subtypes of PCH are characterized by hypoplasia and variable atrophy of the cerebellum and pons (1 -6). The telencephalon gives rise to the cerebral cortex and basal ganglia within the cerebral hemispheres (26) . Cerebral cortical atrophy has been reported in 40% of TSEN54-related PCH patients, a feature that correlates with increasing age, suggesting all patients would display such a phenotype if survival rates were higher (1). Cerebral immaturity is also a key feature for PCH4 diagnosis (1). Also, although less common, microglial and astrocytic pathology have also been reported in the basal ganglia in PCH2 (17) . Therefore, strong TSEN54 expression is apparent in those brain regions affected in PCH during the earlier stages of neurodevelopment. In zebrafish, we observed a ubiquitous expression pattern of tsen54; however, strongest expression was detected within the brain at 24 hpf, in particular the telencephalon and MHB. Ubiquitous tsen54 expression observed as early as the 8-cell stage is compatible with an essential function of this gene during development. Our data confirm results from previous studies in zebrafish embryos using tsen54 RNA probes (24) . Importantly, a comparable TSEN54 expression pattern is observed in humans and zebrafish during early neurodevelopmental stages.
Although obvious anatomical differences exist between the species, comparisons can be made between the brain phenotypes observed in tsen54 morphant zebrafish embryos and TSEN54-related PCH. The presence of progressive microcephaly and cortical shrinkage is a distinctive pathology associated with a PCH2 phenotype (1) . Therefore, the observation of brain hypoplasia in zebrafish embryos following tsen54 knockdown is an expected phenotype. A general neurodevelopmental delay and immaturation of the brain is also associated with the disease (1). PCH is considered a neurodevelopmental, neurodegenerative disorder, however, in contrast to other neurodevelopmental disorders such as lissencephaly (27) , a brain patterning defect is not associated with PCH. Here, we tested for neurodevelopmental abnormalities in our tsen54 MO knockdown model by monitoring the expression Progeny from a tsen54 R228X+/2 in-cross were observed for 3 weeks postfertilization to test for homozygosity. Survival was plotted using the Kaplan-Meier curves. By 9 dpf, 100% of the tsen54 R228X2/2 (yellow line) larvae had died. In comparison, 45% and 62% of the tsen54 R228X+/+ (red line) and tsen54 R228X+/2 (blue line) survived to the 3 weeks post-fertilization time point, respectively. As a comparison to general ENU mutant survival, 72% WT TL larvae (black line) were observed to survive to the 21 dpf stage.
of Fgf8 and Otx2. Expression of these genes was observed within the appropriate regions for this developmental stage thus indicating that a brain patterning deficiency was not associated with a loss of tsen54. Low levels of cell death within the pons have been reported in few PCH patients (5). However, as PCH is a neurodegenerative disorder occurring during early brain development, it is likely that high levels of cell death occur during earlier time points of the disease, rendering these cells unavailable for post-mortem analysis. Indeed, a significant increase in the number of acridine orange fluorescing cells was evident in the brains of tsen54 morphants. Therefore, these data suggest that the brain phenotype caused by the loss of tsen54 function is due to an increased activation of processes leading to cell death and neurodegeneration. It should be noted that not all tissues with high expression of TSEN54 are affected in PCH patients. Since we show here that PCH is in fact a neurodegenerative disease and not a developmental defect per se, other factors must determine the tissue-specific defect. A possible explanation could be a large demand for specific tRNAs for protein synthesis during a specific time in development. As discussed in more detail below, if this demand is not met, cells may degenerate.
The majority of TSEN54-related PCH patients die within the first decade of life (1) . In the most severe cases, a TSEN54 null allele occurring compound heterozygous with the common p.A307S mutation can lead to early post-natal death (1, 2) . We identified the tsen54 R228X ENU mutation and as expected heterozygous mutants were viable. It is likely that possessing two copies of a premature stop-codon mutation leads to a nonfunctional or absent protein; thus, we predicted that the loss of tsen54 would be lethal. To date, no patients have been identified that harbour homozygous premature stop-codon mutations in TSEN54. Due to the potential severity of this type of mutation, it is possible that these patients never survive through prenatal stages. A tsen54 R228X+/2 in-cross produced the expected mendelian ratios (observed following genotyping at 5 dpf), however by 9 dpf, all tsen54 R228X2/2 larvae had died. In comparison, 45% of tsen54 R228X+/+ and 62% of tsen54 R228X+/2 survived beyond the 21 dpf timepoint. These data therefore strongly suggest that homozygosity of the tsen54 premature stop-codon mutation is larval lethal in this model. The absence of a brain phenotype (data not shown) and the survival up to 9 dpf in the tsen54 R228X2/2 mutants may be explained by the persistence of maternal tsen54 RT -PCR using primers located in exons 3 and 6 in rars2 cDNA synthesized from RNA extractions from WT un-injected embryos, CoMO-injected embryos and rars2 exon 6 splice donor site MO-injected embryos. RT -PCR using samples from control embryos produced a band of 246 bp in length. Larger products observed in splice MO-injected embryos indicate abnormal splicing of the rars2 gene. (H) Quantification of phenotypes observed in WT un-injected embryos, human RARS2 mRNA-injected embryos, rars2 ATG MO-injected embryos and rescued embryos co-injected with ATG MO and human mRNA. For each group, 50-100 embryos were analysed. Embryos were classified as displaying normal (white), mild (grey) or severe (black) phenotypes. There is a shift from a predominantly mild-severe phenotype in the rars2 ATG MO group to a predominantly normal phenotype in ATG MO and human RARS2 mRNA co-injection group, thus illustrating the partial rescue of the brain phenotype associated with the loss of rars2.
protein during embryogenesis (28) . Extensive characterization of the tsen54 R228X2/2 mutant line is necessary to fully establish this model as a tool to study the disease mechanisms underlying TSEN54-related PCH.
In both human and zebrafish, the loss of TSEN54/tsen54 function results in a severe region-specific neurological phenotype. Due to the primary function of the TSEN complex, these observations therefore suggest that a high level of tRNA-splicing activity is required within these brain regions during development. Demand for such activity suggests that there is a larger proportion of intron-containing tRNA genes expressed within these regions. Intron-containing tRNA genes are rare in vertebrates (only 6.2% in humans); therefore, tRNA-splicing activity is only required for a small proportion of tRNA genes. However, reduced tRNA-splicing activity may still lead to a reduction in the availability of specific tRNAs, e.g. tRNA tyrosine, where 13 of the 14 tRNA Tyr -(GTA) genes contain an intron. In zebrafish, there is 20-fold more tRNA genes present in comparison to human; however, intron-containing tRNA genes still only represent 6.6% of the total (http://lowelab.ucsc.edu/GtRNAdb/). As in humans, the vast majority of zebrafish tRNA Tyr -(GTA) genes contain an intron (225 out of 236). Hypothetically, therefore, it is reasonable to suggest that in both species, the loss of tRNA-splicing function could lead to a reduction in the availability of tRNA Tyr . If the expression levels of intron-containing tRNA genes are higher in specific brain structures, then a depletion of tyrosine and/or other amino acids could explain the brain-specific degeneration observed in TSEN54-related PCH and the zebrafish tsen54 knockdown model. Due to extensive secondary and tertiary structures, little is known about the spatio-temporal expression levels of different tRNA genes. However, one study has revealed that the expression levels of different human tRNA genes vary greatly between tissues that may reflect translational control based on the availability of certain tRNAs (29) . Future experiments may benefit from examining the levels of intron-containing tRNA genes within the cerebellum and pons in comparison to other tissues. An alternative suggestion for specific susceptibility of the cerebellum and pons in the pathogenesis of PCH may relate to an alternative function of TSEN. For example, the human TSEN complex has been shown to associate with factors involved with pre-mRNA 3 ′ end formation (7) . Therefore, it is feasible that this and/or other currently unknown functions relating to RNA processing may exist for TSEN.
As the RARS2 gene plays a role in the aminoacylation of mitochondrial tRNA Arg (4) and mutations in this gene are found in PCH1 and PCH6 (1,4,13) , we tested whether the knockdown of rars2 in zebrafish resulted in a similar phenotype to tsen54 inhibition. Comparable phenotypes were observed between the rars2 and tsen54 groups. The obvious functional link between TSEN54 and RARS2 is an involvement with tRNA processing. Although specific phenotypical differences exist between TSEN54-and RARS2-related PCH, all patients display hypoplasia and variable atrophy of the cerebellum and pons. The comparable brain phenotype observed following tsen54 and rars2 knockdown therefore provides evidence in a model system that a common disease pathway may exist between PCH subtypes. As for TSEN54, aminoacyl tRNA synthetases (ARSs) are also expressed ubiquitously in humans (30) . In zebrafish at 24 hpf, rars2 is ubiquitously expressed; however, strongest expression is observed within the brain (24) . Mutations in various cytoplasmic and mitochondrial ARS genes have been identified in leukoencephalopathy (DARS2) (31) and different subtypes of Charcot-Marie-Tooth disease [GARS (32) , YARS (33), KARS (34) ]. Recently, mutations in SEPSECS, a protein involved with the synthesis of the amino acid selenocysteine, have been reported to cause progressive cerebello-cerebral atrophy, a neurodevelopmental disorder with comparable phenotypic features to PCH (35) . Taken together with our data, these studies suggest different neuronal populations at different stages of life are susceptible to disruption of specific amino acid availability. Defects in tRNA splicing and tRNA aminoacylation caused by the loss of TSEN54 and RARS2 function, respectively, may ultimately reduce the availability of functionally charged tRNA. Therefore, a common disease pathway involving TSEN54 and RARS2 may relate to the abnormal processing of cytoplasmic and mitochondrial tRNAs within the brain. We cannot yet, however, rule out the potential for alternative functions of these genes in the pathogenesis of PCH. Nevertheless, the identification of a mutation in MED17 (36), encoding a subunit of the mediator complex involved with transcription pre-initiation, in patients with cerebral and cerebellar atrophy (CCA) supports the hypothesis that an unmet demand for protein synthesis at a specific moment in development is the underlying cause of cerebellar atrophy or hypoplasia in CCA and PCH.
MATERIALS AND METHODS
Zebrafish stocks and maintenance
All zebrafish (Danio rerio) procedures were approved by the Academic Medical Center Animal Ethics Committee and experiments complied with standard animal care guidelines. Breeding and maintenance of all zebrafish stocks was performed as described by others (37) . WT TL zebrafish strains were crossed to generate embryos for MO and RNA injections, as well as in situ hybridizations. ENU mutant zebrafish lines were maintained on a mixed AB/TL background. Fertilized embryos were collected and staged according to the standard guidelines (38) .
In situ hybridization using LNA -2OME-modified oligonucleotides to detect TSEN54 expression in human fetal sections Human embryonic tissue was collected and prepared for histological analyses as described (39) . Use of the human embryos for research was approved by the Ethical Committee of the University of Amsterdam, the Netherlands. Pre-hybridization conditioning and hybridization using a human TSEN54 specific, fluorescein-labelled LNA/2OME probe (5 ′ -TcuTuc TcuTgcCauCucC-3 ′ ; where LNA residues are given in capital letters and 2OME in lower case) was performed as described previously (2) . Probes were synthesized by Ribotask ApS, Odense, Denmark. Hybridization signal was detected by incubating the sections in blocking buffer containing anti-fluorescein-Alkaline phosphatase (AP) Fab fragments (1:1000; Roche, Lewes, UK) for 1 h at room temperature. AP signal was detected by using VECTOR Blue AP Substrate Kit (Vector, Burlingame, CA, USA).
Zebrafish whole-mount in situ hybridization using LNA/2OME probes Embryos were dechorionated, fixed in 4% paraformaldehyde (PFA) in 0.1% phosphate buffered saline-Tween (PBST) and stored in methanol at 2208C till further use. Prehybridization conditioning and hybridization using a zebrafish tsen54 specific, fluorescein-labelled LNA/2OME probe (5 ′ -TauCugTccCgcTccCucT-3 ′ ; Ribotask ApS) was performed on whole embryos as described by others (40) . Hybridization signal was detected by incubating the embryos in blocking buffer containing anti-fluorescein-AP Fab fragments (1:2000; Roche) with agitation overnight at 48C. AP staining was performed using 5-bromo-4-chloro-3-indolyl phosphate/ nitro blue tetrazolium substrate.
MO injections
MOs (Gene-tools, LLC, Philomath, OR, USA) were designed around the start codon (ATG) and the exon 8 splice donor site of the zebrafish tsen54 gene (ATG:
For the zebrafish rars2 gene, MOs were designed against the ATG and the exon 6 splice donor sequence (ATG: 5 ′ -CACTCCTCCTGAAAAAACACGCCA T-3 ′ ; Ex6splice: 5 ′ -CACACACACAGTAAACTGACCTG AA-3 ′ ). Standard CoMOs were also provided by Gene-tools. Using fine glass needles and a microinjector (World Precision Instruments, Sarasota, FL, USA), 1 -4-cell stage embryos were injected directly into the yolk sac with 2.5 ng ATG MO, 3.2 ng splice MO or 6.6 ng CoMO. Embryos were allowed to recover in E3 medium stored at 288C before fixation at various time points.
Human mRNA in vitro transcription and injections
Human TSEN54 cDNA cloned into the pCMV-SPORT6 vector (NIH_MGC_71) and human RARS2 cDNA cloned into the pOTB7 vector (NIH_MGC_44) were obtained from the Mammalian Gene Collection (NIH, Bethesda, USA). The TSEN54 insert was excised using XhoI and EcoRI; the RARS2 insert was excised using BamHI and XhoI. Both cDNA sequences were ligated into separate pCS2+ vectors. The TSEN54 and RARS2 constructs were linearized with Asp718 and Not1, respectively, and in vitro transcription was performed using the SP6 mMESSAGE mMACHINE kit (Ambion, Warrington, UK). For injections, 233 or 555 pg of TSEN54 and RARS2 mRNA, respectively, was injected per embryo either alone as a control or in combination with the ATG MO. For each group, 50-100 embryos at 24 hpf were classified and counted as displaying phenotypes described as either normal (appeared as WT), mild (slightly smaller head, slightly reduced brain structure definition) or severe (small head, complete loss of brain structural definition).
RT -PCR
To confirm specific targeting of the splice MO, total RNA was extracted from 50 injected embryos using TRIzol (Invitrogen, Germany) and chloroform for phase separation and isopropanol precipitation. For the reverse transcription reaction, 1 mg of RNA was mixed with 125 pmol/ml OligodT 12 -VN and denatured for 10 min at 728C. First-strand cDNA was synthesized using SuperscriptII enzyme (Invitrogen) and incubating at 428C for 1 h. For tsen54 ex8 splice MO, a region of 696 bp spanning exons 7 and 10 was amplified using the following primers: 5 ′ -CAGCATCGGACAAACAGAAG-3 ′ and 5
′ -ACTGGTCTGACGGGGACA-3 ′ (Sigma-Aldrich). For rars2 ex6 splice MO, a region of 246 bp spanning exons 3 and 6 was amplified using the following primers:
Whole-mount in situ hybridization using DIG-labelled RNA probes fgf8 (18) and otx2 (20) were linearized with EcoRV and EcoRI, respectively, and digoxigenin (DIG)-RNA probes were synthesized using the SP6/T7 polymerase RNA labelling kit (Roche). Zebrafish embryos (24-30 hpf) were dechorionated, fixed overnight at 48C in 4% PFA in 0.1% PBST and stored in methanol at 2208C till further use. Whole-mount in situ hybridization was performed as described by others (41) .
In vivo cell death assay
Live embryos were incubated for 30 min in the dark at 288C in water containing 2 mg/ml acridine orange (Sigma-Aldrich). Embryos were washed five times in water prior to imaging. The numbers of fluorescing cells in focus were counted within the brain in a region encapsulating the tip of the forebrain to the ear. Dying cells within the eye were omitted from the analysis. Fluorescing cells were counted in 10-20 embryos/larvae per condition. The mean number of fluorescing cells + standard error was plotted. One-way ANOVA with the Newman -Keuls multiple comparisons test was performed for statistical analysis.
ENU mutagenesis screen
ENU mutation screening was performed using a TILLING (targeting induced local lesions IN genomics) approach with a frozen archive of genomic DNA derived from mutagenized F1 zebrafish at the Hubrecht Institute, Utrecht, the Netherlands, as described previously (42) . Exon 8 of the tsen54 gene was amplified using the following nested PCR primers (Primer 1: 5 ′ -GGGACTTCAGCAGCATTAG-3 ′ ; Primer 2: 5 ′ -AGGAGATCTGAGCGTTTGG-3 ′ ; Primer 3: 5 ′ -CCAGT CTTTACCCAGTCACC-3 ′ ; Primer 4: 5 ′ -CTTCCAACAAT CTTTCTTTCC-3 ′ ; Sigma-Aldrich). The first PCR was performed using primers 1 and 4. The second PCR was performed using primers 2 and 3, which contained universal M13 forward (M13F) and M13 reverse (M13R) adaptor sequences at their 5 ′ ends, respectively. Mutation detection and verification was therefore performed by sequencing the internal nested PCR product using M13F (5 ′ -TGTAAAACGACGGCCAGT-3 ′ ; Sigma-Aldrich) and M13R primers (5 ′ -AGGAAACAGCTAT GACCAT-3 ′ ; Sigma-Aldrich). PCR products were sequenced as described previously (1) .
Taqman genotyping
Following identification of the individual heterozygous c.682C . T tsen54 mutant (hu5985) in the live F1 library, the mutation was backcrossed onto a WT AB background for five generations to reduce the number of potentially confounding ENU mutations. For each subsequent generation, genotyping was performed using a Taqman single-nucleotide polymorphism (SNP) genotyping approach (Applied Biosystems, Warrington, UK). Briefly, fish were anaesthetized in 250 mg/l tricaine (MS-222; Sigma-Aldrich), and a small portion of the caudal fin was removed with a scalpel. Fin clips were digested with lysis buffer containing 0.1 mg/ml of proteinase K at 608C for 1 h. Following DNA quantification, 10 ng of DNA was added to 1 × 5 ml of Roche Fast-Start universal probe mix (Roche) containing 40× Taqman SNP assay probe (designed and generated by Applied Biosystems; FAM and VIC dye-labelled). Realtime PCR was then performed using a Roche LightCycler 480 for 40 cycles (denatured at 958C for 15 s, annealed/amplified at 608C for 1 min). Allelic discrimination was analysed using the Roche LightCycler software version 1.5.
Survival analysis in tsen54
R228X mutant zebrafish
Progenies from an in-cross mating of tsen54 R228X+/2 adults were raised for 3 weeks. Dead larvae were removed from the tank twice daily and DNA was extracted immediately before freezing. At 21 dpf, all surviving larvae were humanely sacrificed and DNA was extracted. All dead and surviving embryos were genotyped as described above. Survival of tsen54 R228X2/2 larvae was examined using the KaplanMeier analysis (Graphpad Prism, version 5) to produce survival curves for each genotype. Similarly, progenies from an in-cross mating of WT TL adults were raised for 3 weeks and dead larvae were counted on a daily basis for survival analysis.
